|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.5599 - 0.5599|
|52 Week Range||0.2000 - 1.4000|
|Beta (5Y Monthly)||1.64|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Provides advancement for its immunotherapy technology against brain tumors into human clinical trialsCLEVELAND, OH / ACCESSWIRE / November 18, 2020 / NovAccess Global Inc.
NovAccess Global Enhances Scientific Advisory Board with Distinguished Industry Experts and adds Chief Financial OfficerCLEVELAND, OH / ACCESSWIRE / October 21, 2020 / NovAccess Global Inc.
Leadership by world-renown cancer researcher signals commitment to driving current and forthcoming biomedical opportunitiesCLEVELAND, OH / ACCESSWIRE / October 15, 2020 / NovAccess Global, Inc.